fashion -WSS

fashion

author：hotspot 2025-10-02 11:08:28 - browse：43974

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Glen Campbell's doctor discusses his public struggle with Alzheimer's

entertainment

WSS

Big Tobacco's 'harm reduction': Is it for real, or a sham?

When prostate cancer spreads, where it goes matters

Criminal prosecution for violating HIPAA: an emerging threat

Criminal prosecution for violating HIPAA: an emerging threat

Google and Epic fight stronger regulation of AI in health care

Criminal prosecution for violating HIPAA: an emerging threat

explore

fashion

hotspot

Jerome Adams on the need for new antivirals for Covid

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Dobbs anniversary: the lost opportunity of abortion as health care

Military medical care influenced by rank and race, new study finds

Medicare details structure of new drug price negotiation program

Startup Neumora takes a novel depression drug to Phase 3

New air purifier tech could be key to improving indoor air quality

Addiction experts warn against a second 'war on drugs'

United colonoscopy coverage change 'may cost lives,' doctors say

In early work, researchers turn to CRISPR to treat Alzheimer's

focus

Arc Institute generative AI designs new CRISPR systems

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Glen Campbell's doctor discusses his public struggle with Alzheimer's

When prostate cancer spreads, where it goes matters

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

entertainment

focus

entertainment

focus